Cambridge UK, January 2010 - Antitope Ltd. today announced a research agreement with Agence Nationale de Recherches sur le SIDA et les hepatitives virales (ANRS, France), INSERM (France) and Baylor Research Institute (BRI, Dallas, Texas USA) for the generation of multiple humanized antibodies. Under the Agreement, Antitope will apply its proprietary Composite Human AntibodyTM technology in order to generate therapeutic antibodies for the treatment of HIV/AIDS, hepatitis C infection, tuberculosis and cancer.
